Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) – Pipeline Review, H2 2016’, provides in depth analysis on Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted pipeline therapeutics.

The report provides comprehensive information on the Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)

The report reviews Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics and enlists all their major and minor projects

The report assesses Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Adamis Pharmaceuticals Corporation

Argos Therapeutics, Inc.

Asterias Biotherapeutics, Inc.

e-Therapeutics Plc

F. Hoffmann-La Roche Ltd.

Inovio Pharmaceuticals, Inc.

Invectys SA

Johnson & Johnson

Komipharm International Co., Ltd.

Mediolanum farmaceutici S.p.A.

Ultimovacs AS

Vaxon Biotech

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC

2.7.7.49) Overview 9

Therapeutics Development 10

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC

2.7.7.49) - Products under Development by Stage of Development 10

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC

2.7.7.49) - Products under Development by Therapy Area 11

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC

2.7.7.49) - Products under Development by Indication 12

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC

2.7.7.49) - Pipeline Products Glance 14

Late Stage Products 14

Early Stage Products 15

Unknown Stage Products 16

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC

2.7.7.49) - Products under Development by Companies 17

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC

2.7.7.49) - Products under Development by Universities/Institutes 21

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC

2.7.7.49) - Therapeutics Assessment 23

Assessment by Monotherapy/Combination Products 23

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC

2.7.7.49) - Companies Involved in Therapeutics Development 30

Adamis Pharmaceuticals Corporation 30

Argos Therapeutics, Inc. 31

Asterias Biotherapeutics, Inc. 32

e-Therapeutics Plc 33

F. Hoffmann-La Roche Ltd. 34

Inovio Pharmaceuticals, Inc. 35

Invectys SA 36

Johnson & Johnson 37

Komipharm International Co., Ltd. 38

Mediolanum farmaceutici S.p.A. 39

Ultimovacs AS 40

Vaxon Biotech 41

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC

2.7.7.49) - Drug Profiles 42

AGS-499 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

ASTVAC-1 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

ASTVAC-2 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

ETS-2300 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Gene Therapy to Activate Telomerase for Alzheimer's Disease - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Gene Therapy to Activate Telomerase for Alzheimer’s Disease and Atherosclerosis - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Gene Therapy to Activate Telomerase for Aplastic Anemia - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

GX-301 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

imetelstat sodium - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

INO-1400 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

INO-5400 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

INVAC-1 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

KML-001 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

rocapuldencel-T - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

Small Molecule to Target Telomerase for Lung Cancer - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Telin - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

TeloB-VAX - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

tertomotide - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

UCPVax - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

UV-1 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Vaccine to Target Telomerase for Oncology - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

Vaccine to Target Telomerase Reverse Transcriptase for Solid Tumor - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

Vbx-016 - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

Vbx-026 - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

Vx-001 - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Vx-006 - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC

2.7.7.49) - Dormant Projects 85

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC

2.7.7.49) - Discontinued Products 89

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC

2.7.7.49) - Featured News & Press Releases 92

Sep 12, 2016: Geron Provides Update on Imetelstat Trials Being Conducted by Janssen 92

Jul 13, 2016: Geron Announces Issuance of U.S. Patents Related to Imetelstat 93

Jun 13, 2016: Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 in Metastatic Renal Cell Carcinoma Following Interim Data Review 94

May 02, 2016: Asterias Biotherapeutics Announces Oral Presentation at ASGCT 19th Annual Meeting 94

Apr 20, 2016: Geron Announces Two Imetelstat Poster Presentations at the American Association for Cancer Research Annual Meeting 95

Mar 23, 2016: Argos Therapeutics Announces Initiation of a Phase 2 Clinical Trial of AGS-003 for the Treatment of Non-small Cell Lung Cancer in Combination with Standard-of-Care Chemotherapy 97

Mar 02, 2016: New trial launched to test cancer vaccine 97

Feb 24, 2016: Asterias Biotherapeutics Announces Successful End-of-Phase 2 Meeting with FDA for AST-VAC1 99

Jan 21, 2016: Asterias Biotherapeutics Announces Completion of Transfer of AST-VAC2 Manufacturing Process to Cancer Research UK as Milestone Towards Initiating Phase 1/2 Clinical Trial 100

Jan 14, 2016: Geron Announces Initiation of Janssen Phase 2/3 Clinical Trial of Imetelstat in Myelodysplastic Syndromes 101

Dec 10, 2015: Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma Following Second Planned Interim Analysis 102

Nov 05, 2015: Geron Announces Presentations at American Society of Hematology Annual Meeting 102

Nov 05, 2015: Janssen to Present Posters on Imetelstat at the 2015 American Society of Hematology Annual Meeting 103

Oct 30, 2015: Invectys starts the third dose level of its phase I clinical trial evaluating INVAC-1, an innovative anti-cancer therapeutic vaccine 104

Sep 16, 2015: Geron Announces Initiation of Janssen Phase 2 Clinical Trial of Imetelstat in Myelofibrosis 104

Appendix 106

Methodology 106

Coverage 106

Secondary Research 106

Primary Research 106

Expert Panel Validation 106

Contact Us 106

Disclaimer 107

List of Tables

List of Tables

Number of Products under Development for, H2 2016 10

Number of Products under Development by Therapy Area, H2 2016 11

Number of Products under Development by Indication, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Comparative Analysis by Unknown Stage Development, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Products under Development by Companies, H2 2016 18

Products under Development by Companies, H2 2016 (Contd..1) 19

Products under Development by Companies, H2 2016 (Contd..2) 20

Number of Products under Investigation by Universities/Institutes, H2 2016 21

Products under Investigation by Universities/Institutes, H2 2016 22

Assessment by Monotherapy/Combination Products, H2 2016 23

Number of Products by Stage and Mechanism of Action, H2 2016 25

Number of Products by Stage and Route of Administration, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 29

Pipeline by Adamis Pharmaceuticals Corporation, H2 2016 30

Pipeline by Argos Therapeutics, Inc., H2 2016 31

Pipeline by Asterias Biotherapeutics, Inc., H2 2016 32

Pipeline by e-Therapeutics Plc, H2 2016 33

Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 34

Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 35

Pipeline by Invectys SA, H2 2016 36

Pipeline by Johnson & Johnson, H2 2016 37

Pipeline by Komipharm International Co., Ltd., H2 2016 38

Pipeline by Mediolanum farmaceutici S.p.A., H2 2016 39

Pipeline by Ultimovacs AS, H2 2016 40

Pipeline by Vaxon Biotech, H2 2016 41

Dormant Projects, H2 2016 85

Dormant Projects (Contd..1), H2 2016 86

Dormant Projects (Contd..2), H2 2016 87

Dormant Projects (Contd..3), H2 2016 88

Discontinued Products, H2 2016 89

Discontinued Products (Contd..1), H2 2016 90

Discontinued Products (Contd..2), H2 2016 91

List of Figures

List of Figures

Number of Products under Development for, H2 2016 10

Number of Products under Development by Therapy Area, H2 2016 11

Number of Products under Development by Top 10 Indication, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 23

Number of Products by Mechanism of Actions, H2 2016 24

Number of Products by Stage and Mechanism of Actions, H2 2016 24

Number of Products by Routes of Administration, H2 2016 26

Number of Products by Stage and Routes of Administration, H2 2016 26

Number of Products by Molecule Types, H2 2016 28

Number of Products by Stage and Molecule Type, H2 2016 28

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports